Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer.

Subjects

Subjects :

Humans
Antibodies, Monoclonal, Humanized therapeutic use
Urinary Bladder Neoplasms drug therapy
Antibodies, Monoclonal adverse effects
Antibodies, Monoclonal therapeutic use
Carcinoma, Transitional Cell drug therapy
Urologic Neoplasms drug therapy

Details

Language :

English

ISSN :

1533-4406

Volume :

390

Issue :

10

Database :

MEDLINE

Journal :

The New England journal of medicine

Publication Type :

Editorial & Opinion

Accession number :

38446680

Full Text :

https://doi.org/10.1056/NEJMe2400311